Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Extracellular vesicles (EVs) are ubiquitously secreted nanoparticles that modulate the activities of recipient cells either through the transfer of bioactive cargo or by surface receptor-mediated signalling. EVs derived from dendritic cells are increasingly recognised as promising platforms for therapeutic cancer vaccines, owing to their immunostimulatory cargo, their capacity to transfer preformed peptide-major histocompatibility complexes to antigen-presenting cells, and their ability, in some cases, to directly activate cognate T cells. Despite encouraging preclinical results, EV-based cancer vaccines have demonstrated limited clinical efficacy, constrained by suboptimal immunogenicity, poor lymphoid targeting, and suppression within the tumour microenvironment. Several strategies-including prioritising tumour-specific neoantigens, co-administering adjuvants and immunotherapies, optimising EV production and delivery protocols, and engineering EVs with tailored characteristics-aim to overcome these limitations and improve clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imm.70033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A new frontier in oncology: Understanding the landscape of cancer vaccines.
J Oncol Pharm Pract
September 2025
Department of Research & Development, Squad Medicine and Research (SMR), Amadalavalasa, Andhra Pradesh, India.
Cancer vaccines represent a transformative shift in oncology, aiming to prevent malignancies or treat established cancers by training the immune system to recognize tumor-specific or tumor-associated antigens. This review explores the diverse platforms and mechanisms supporting cancer vaccines, ranging from prophylactic vaccines such as HPV and hepatitis B vaccines that have significantly reduced virus-related cancers to therapeutic vaccines like Sipuleucel-T and T-VEC that extend survival in prostate cancer and melanoma. Vaccine types are classified, and delivery platforms including mRNA, peptide, dendritic cell and viral vector-based approaches are examined alongside pivotal clinical trial outcomes.
View Article and Find Full Text PDFOuter Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.
J Extracell Vesicles
September 2025
IRSD, Université de Toulouse, INSERM, INRAE, ENVT, Toulouse, France.
Outer membrane vesicles (OMVs) are nanosized vesicles naturally secreted by Gram-negative bacteria and represent a promising platform for vaccine development. OMVs possess inherent immunostimulatory properties due to the presence of pathogen-associated molecular patterns (PAMPs), providing self-adjuvanting capabilities and the ability to elicit both innate and adaptive immune responses. This review outlines the advantages of OMVs over traditional vaccine strategies, including their safety, modularity, and the potential for genetic engineering to enable targeted antigen delivery.
View Article and Find Full Text PDFHuman papillomavirus (HPV) vaccination in women with conisation.
Cochrane Database Syst Rev
September 2025
Institute for Evidence in Medicine, Medical Center - University of Freiburg / Medical Faculty - University of Freiburg, Freiburg, Germany.
Rationale: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.
View Article and Find Full Text PDFOncolytic Hydrogel Enhances Immune Checkpoint Blockade by Generating Vaccine, Remodeling Tumor Physical and Metabolic Barriers.
ACS Nano
September 2025
School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Although traditional immunogenic cell death (ICD) inducers generate vaccines (ISV) to potentiate antiprogrammed cell death ligand 1 (anti-PDL1) antibodies therapy, their efficacy remains limited. This limitation may be attributed to the physical barrier created by extracellular matrix (ECM) and immunosuppressive metabolic barrier mediated by adenosine. Here, we report an oncolytic polymer (OP), a well-designed ε-polylysine derivative with ICD-inducing capacity, which can simultaneously facilitate the release of endogenous ECM-degrading enzyme, Cathepsin B.
View Article and Find Full Text PDFBreakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).